Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CTS Eventim AG & Co. KGaA (EVD.DE)

XETRA - XETRA Delayed Price. Currency in EUR
66.25+0.80 (+1.22%)
At close: 05:35PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close65.45
Open65.50
Bid66.20 x N/A
Ask66.30 x N/A
Day's Range65.20 - 66.70
52 Week Range40.32 - 67.75
Volume98,600
Avg. Volume103,584
Market Cap6.359B
Beta (5Y Monthly)1.37
PE Ratio (TTM)43.30
EPS (TTM)1.53
Earnings DateMar 23, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 09, 2019
1y Target Est62.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for EVD.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      KAMP LA K-POP MEGA CONCERT BRINGS TOGETHER HISTORIC LINEUP AT THE ROSE BOWL IN LOS ANGELES

      South Korea-based immersive entertainment brand KAMP Global, in partnership with Eventim Live Asia (ELA), proudly present KAMP LA 2022. On October 15th and 16th, 2022, at the Rose Bowl Stadium, the most legendary venue in Los Angeles, KAMP LA 2022 will deliver one of the biggest live-music K-pop experiences in history.

    • GlobeNewswire

      T2 Biosystems Announces First Quarter 2022 Financial Results

      Results driven by strong sepsis-focused instrument placements in the United StatesLEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the first quarter ended March 31, 2022. Recent Highlights Achieved first quarter total revenue of $7.2 million, including product revenue of $3.8 million and research contribution reven

    • GlobeNewswire

      T2 Biosystems Announces Receipt of Nasdaq Delisting Notice

      Company has Filed an Appeal and will Present a Plan to Regain ComplianceLEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on May 5, 2022 it received a letter from The Nasdaq Stock Market informing the Company that its shares of common stock have failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Global Ma

    Advertisement
    Advertisement